Home > Boards > US Listed > Medical - Drugs > AstraZeneca PLC (AZN)

P.S.The EMC is the European Medical Commission.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Equitiesduke  Member Profile
 
Followed By 3
Posts 194
Boards Moderated 0
Alias Born 07/11/14
160x600 placeholder
BRILINTA Met Primary Endpoint in the Phase III THALES Trial in Stroke Business Wire - 1/27/2020 7:00:00 AM
AstraZeneca: Enhertu Phase 2 Trial Meets Primary Endpoint Dow Jones News - 1/27/2020 2:58:00 AM
AstraZeneca's Brilinta Met Primary Endpoint in Phase Three Stroke Trial Dow Jones News - 1/27/2020 2:54:00 AM
AstraZeneca to Recover Global Rights to Brazikumab From Allergan Dow Jones News - 1/27/2020 2:48:00 AM
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep PR Newswire (US) - 1/27/2020 1:15:00 AM
AstraZeneca Pledges $1 Billion to Cut CO2 Emissions Dow Jones News - 1/22/2020 5:38:00 AM
Myriad Submits sPMA for BRACAnalysis CDx Test Dow Jones News - 1/21/2020 7:58:00 AM
AstraZeneca, Merck Get FDA Priority Review for Lynparza in Form of Prostate Cancer Dow Jones News - 1/21/2020 7:43:00 AM
Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prost... GlobeNewswire Inc. - 1/21/2020 7:05:10 AM
AstraZeneca: FDA Gives Orphan Drug Status to Two Liver Cancer Drugs Dow Jones News - 1/20/2020 2:48:00 AM
AstraZeneca's Prostate Cancer Supplemental Drug Gets U.S. Approval Dow Jones News - 1/20/2020 2:46:00 AM
My Green Lab Working with AstraZeneca to Implement Green Labs Program Dow Jones News - 1/14/2020 12:03:00 PM
AstraZeneca Faces $100 Million Impairment After Disappointing Epanova Data -- Update Dow Jones News - 1/13/2020 8:22:00 AM
AstraZeneca, Merck Get FDA Priority Review for Lynparza in Advanced Ovarian Cancer Dow Jones News - 1/13/2020 7:43:00 AM
AstraZeneca to Discontinue Epanova Trial Following Disappointing Data Dow Jones News - 1/13/2020 2:37:00 AM
FDA to Review Extending Uses for AstraZeneca-Controlled Drug Dow Jones News - 1/6/2020 7:51:00 AM
FARXIGA Granted FDA Priority Review For Patients With Heart Failure With Reduced Ejection Fraction Business Wire - 1/6/2020 7:00:00 AM
AstraZeneca, Merck Get FDA OK for Lynparza in Pancreatic Cancer Indication Dow Jones News - 12/30/2019 7:49:00 AM
Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germlin... GlobeNewswire Inc. - 12/30/2019 7:05:10 AM
LYNPARZA (Olaparib) Approved in the US as a 1st-line Maintenance Treatment of Germline BRCA-mutated Metastatic Pancreatic Can... Business Wire - 12/30/2019 6:55:00 AM
FDA Approves AstraZeneca's Lynparza for Pancreatic Cancer Dow Jones News - 12/30/2019 2:42:00 AM
ENHERTU (fam-trastuzumab deruxtecan-nxki) Approved in the US for HER2-Positive Unresectable or Metastatic Breast Cancer Follo... Business Wire - 12/20/2019 6:04:00 PM
AstraZeneca Sells Rights to Two Cancer Medicines for $181 Million Up Front Dow Jones News - 12/20/2019 2:41:00 AM
AstraZeneca, Merck Say FDA Panel Recommends Lynparza in Pancreatic Cancer Dow Jones News - 12/17/2019 3:05:00 PM
AstraZeneca: Imfinzi Approved in China for Stage III Nonsmall-Cell Lung Cancer Dow Jones News - 12/12/2019 2:53:00 AM
Equitiesduke   Friday, 04/27/18 11:21:42 AM
Re: Equitiesduke post# 138
Post # of 148 
P.S.
The EMC is the European Medical Commission.
Info now on Dow Jones Newswire.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist